THE CLINICAL STUDY OF PRIMARY DRUG RESISTANCE IN HIV POSITIVE PATIENTS

Dr Rajesh meena, Dr. Baldev Meena, Dr. O. P. Meena

Abstract


Introduction: India has the second largest number of HIV infections in the world. Since the introduction of generic antiretrovirals (ARVs) in 2000,
there has been a steep increase in the number of individuals initiating antiretroviral therapy (ART) primarily due to the reduction in cost of ART.
Highly active antiretroviral therapy (HAART) has dramatically improved survival and quality of life in people living with HIV and AIDS.
Objective: Study of WHO stage, CD4 count and viral load after starting 2nd line ART.
Materials And Methods: Patients were given prophylactic treatment for OI based on NACO guidelines. Patients were closely observed and
followed up for clinical failure, immunological failure and virological failure.
Results : Mean viral load in treatment failure was 231331 copies/ml and after 2nd line ART it was 697.63 copies/ml (P<0.05). 37% patients were in
WHO stage I and 25% patients in stage IV who are on 1st line ART. After 2nd line ART 58% patients were in WHO stage I and 6% patients in WHO
stage IV. 43 patients on 1st line ART were in between 40-49 kg. 42 patients on 2nd line ART were in between 40-49 kg weight. Mean weight of
treatment failure patients was 47.17 kg while mean weight after 2nd line ART was 47.8 kg (P>0.05). Weight improvement required longer time
monitoring than immunological and virological monitoring.
Conclusion : Patients, who are not responding to 1st line ART, must switch over to 2nd line ART as early as possible after ruling out adherence issue
and significant drug interaction and co morbid conditions.


Keywords


AIDS, ARV, Antiretroviral Therapy (ART), WHO Staging  

Full Text:

PDF

References


Kumarasamy N, Vallabhaneni S, Cecelia AJ, Yepthomi T, Balakrishnan P. Reasons for Modification of Generic Highly Active Antiretroviral Therapeutic Regimens Among Patients in Southern India. J Acquir Immune Defic Syndr 2006;41:53-8.

Mbisa JL, Nikolenko GN, Pathak VK. Mutations in the RNase H primer grip domain of murine leukemia virus reverse transcriptase decrease efficiency and accuracy of plus-strand DNA transfer. J Virol 2005;79:419-27.

Tee KK, Saw TL, Pon CK, Kamarulzaman A, Ng KP. The evolving molecular epidemiology of HIV type 1 among injecting drug users (IDUs] in Malaysia. AIDS Res Hum Retrov 2005;21:1046-50.

Geretti AM. HIV-1 subtypes: Epidemiology and significance for HIV management. Curr Opin Infect Dis 2006;19:1-7.

Tozzi V, Corpolongo A, Bellagamba R, Narciso P. Managing patients with sexual transmission of drug-resistant HIV. Sex Health 2005;2:135-42.

Balakrishnan P, Kumarasamy N, Kantor R, Solomon S. HIV type 1 genotypic variation in an antiretroviral treatment-naive population in southern India AIDS Res Hum Retrov 2005;21:301-5.

NACO guidelines, 2012.

Hosseinipour Mina C, van Oosterhout JJ, Weigel R, et al. The public health approach to identify antiretroviral therapy failure: high-level nucleoside reverse transcriptase inhibitor resistance among Malawians failing first-line antiretroviral therapy. AIDS. 2009;23(9):1127–1134..

S. Sinha, H. Ahmad, R. C. Shekhar, N. Kumar, L. Dar, J. C. Prevalence of HIV Drug Resistance Mutations in HIV Type 1 Isolates in Antiretroviral Therapy Naive Population from Northern India. AIDS Res Treat. 2012;2012:905823.

Somnuek Sungkanuparph, Rebecca Oyomopito, Sunee Sirivichayakul, Thira Sirisanthana, Christopher K. C. Lee. HIV-1 Drug Resistance Mutations Among Antiretroviral-Naïve HIV-1–Infected Patients in Asia: Results From the TREAT Asia Studies to Evaluate Resistance-Monitoring Study. Clinical Infectious Diseases 2011;52(8):1053–1057.


Refbacks

  • There are currently no refbacks.